Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
Ironwood Pharmaceuticals, Inc., a gastrointestinalfocused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved LINZESS® (linaclotide) as a method of treatment. once-daily treatment of dysfunctional pediatric patients 6 to 17 years of age. constipation. LINZESS…